|Day Low/High||121.15 / 122.26|
|52 Wk Low/High||72.13 / 121.41|
In the immediate aftermath of the Obamacare rollout, pharma and healthcare M&A fell. Now, however, it's back up, on deals like Monday morning's Covidien - Medtronic announcement,
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.
If you step out of the blinding spotlight, the truly rewarding buying opportunities become obvious.
The stock is retreating from overbought levels, and it has upside catalysts ahead.
Is there any truth behind 'Sell in May and Go Away?' Let's look at the data for answers.